福泰制药 VRTX 深 沪
等待开盘 06-25 09:30:00 美东时间
477.46
+9.040
+1.93%
华盛通- 最 高480.855
- 今 开471.38
- 成交量 51.73万股
- 最 低 469.925
- 昨 收 468.42
- 总市值 1211.82亿
- 52周最高 507.92
- 市盈率 静 31.16
- 换手率 0.20%
- 52周最低 362.50
- 委 比 -47.92%
- 总股本 2.54亿
- 历史最高 519.88
- 量 比 0.41
- 振 幅 2.33%
- 历史最低 26.50
- 每 手 1
- 风险率 28.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biotech breakout: iShares Biotechnology ETF hits all-time high
The biotechnology sector continued its advance on Tuesday, with the iShares Biotechnology ETF (IBB) reaching a record intraday high of $179.95 as investor interest in the industry remained strong. The...
06-24 02:52
福泰制药 股价放量上涨3.36% 报466.79
福泰制药（VRTX）最新交易日收涨3.36%，报466.79美元，伴随成交量显著攀升，机构参与度较高，股价已突破短期阻力位，站稳关键心理关口与移动平均线之上，短...
06-23 10:39
Vertex Pharmaceuticals VRTX逆势上涨2.66% 板块利空下走出独立行情
福泰制药（VRTX）盘中强势突破460美元关口，走出独立上涨行情，当前股价报463.65美元，较昨日收盘价上涨2.66%，盘中最高触及464.87美元，正在测试...
06-22 22:12
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported new clinical data showing that CASGEVY (exagamglogene autotemcel) delivered efficacy and safety outcomes in children ages 5 to 11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) The data were consistent ...
06-12 00:20
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
CervoMed Inc. has secured $10.5 million in a private placement to extend its cash runway into Q2 2027 and advance neflamapimod, a drug targeting dementia with Lewy bodies (DLB), into Phase 3 development. The funding will also support upcoming milestones, including 24-week data from a Phase 2a trial in nonfluent variant primary progressive aphasia (nfvPPA) and the initiation of a Phase 2a trial in amyotrophic lateral sclerosis (ALS). Key strategic...
06-10 11:30
当下500美元最值得投资的股票
因医疗保健行业近年表现落后且前景不明，部分投资者避开该行业，但这或带来趁低买入顶级医疗保健股的机会。推荐艾伯维（纽约证券交易所代码：ABBV）和福泰制药（纳斯达...
06-04 15:38
Povetacicept治疗IgA肾病的生物制品上市许可申请获FDA受理，并纳入...
FDA设定的处方药用户付费法案（PDUFA）目标行动日期为2026年11月30日 6月1日，再鼎医药合作伙伴Vertex Pharmaceuticals I...
06-02 17:05
福泰制药盈利增长受市场共识预期修正推动
Vertex制药公司（VRTX）过去一个月股价涨5.6%，优于Zacks医疗——生物医学与遗传学行业2.9%的涨幅，略逊于Zacks标准普尔500综合指数6....
06-01 22:22
Vertex Pharmaceuticals Receives FDA Acceptance For Its Biologics License Application Submission For Povetacicept To Treat Immunoglobulin A Nephropathy
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational
06-01 20:03
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics announced that senior management will participate in three investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 at 9:55 a.m. ET, William Blair’s 46th Annual Growth Stock Conference on June 3 at 4:40 p.m. CT, and Goldman Sachs’ 47th Annual Global Healthcare Conference on June 9 at 2:40 p.m. ET. Live webcasts and replays will be available on the company’s website. CRISPR Therapeutics is a leadi...
05-28 12:00
